NeoGenomics (NEO)
(Delayed Data from NSDQ)
$13.53 USD
-0.01 (-0.07%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $13.52 -0.01 (-0.07%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.53 USD
-0.01 (-0.07%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $13.52 -0.01 (-0.07%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
Zacks News
NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
NeoGenomics (NEO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Here's What Key Metrics Tell Us About NeoGenomics (NEO) Q2 Earnings
by Zacks Equity Research
Although the revenue and EPS for NeoGenomics (NEO) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Here's What Key Metrics Tell Us About NeoGenomics (NEO) Q1 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for NeoGenomics (NEO) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 33.33% and 4.29%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Myriad Genetics (MYGN) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?
by Zacks Equity Research
Absci Corporation (ABSI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
All You Need to Know About NeoGenomics (NEO) Rating Upgrade to Buy
by Zacks Equity Research
NeoGenomics (NEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Does NeoGenomics (NEO) Have the Potential to Rally 43.34% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 43.3% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Predict a 29.57% Upside in NeoGenomics (NEO): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 29.6% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
NeoGenomics (NEO) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for NeoGenomics (NEO) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
NeoGenomics (NEO) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 400% and 1.73%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Top Stock Picks for Week of January 15, 2024
by Panel Of Zacks Experts
An Interesting Mid Cap Stock and a Small-Cap Provider of Cancer Genetics Diagnostics for Your Consideration.
NeoGenomics and Marvell Technology have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
NeoGenomics and Marvell Technology are part of the Zacks Bull and Bear of the Day article.
Bull of the Day: NeoGenomics (NEO)
by Kevin Cook
Small-cap leader in oncology diagnostics is on sale after patent litigation takes a bite
Best Momentum Stocks to Buy for January 9th
by Zacks Equity Research
NEO, WIX and LNW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 9, 2024.
New Strong Buy Stocks for January 9th
by Zacks Equity Research
NEO, WIX, LNW, TM and RBB have been added to the Zacks Rank #1 (Strong Buy) List on January 9, 2024.
Wall Street Analysts See a 28.17% Upside in NeoGenomics (NEO): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 28.2% in NeoGenomics (NEO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Compared to Estimates, NeoGenomics (NEO) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for NeoGenomics (NEO) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeoGenomics (NEO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
NeoGenomics (NEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Think NeoGenomics (NEO) Could Surge 35.08%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 35.1% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Bull of the Day: NeoGenomics (NEO)
by Kevin Cook
Diagnostic lab companies were hit by new FDA rules but this cancer fighter rebounds under 3X sales
NeoGenomics and SolarEdge Technologies have been highlighted as Zacks Bull and Bear of the Day
by Santanu Roy
NeoGenomics and SolarEdge Technologies are part of the Zacks Bull and Bear of the Day article.
NeoGenomics (NEO) Soars 8.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
NeoGenomics (NEO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.